A network meta-analysis of 32 randomized controlled trials with 28,888 adult patients reveals that balanced crystalloid solutions offer better outcomes for patients with sepsis or septic shock, including lower mortality, reduced incidence of acute kidney injury, and shorter intensive care unit and hospital stays. The study contradicts the 2021 Sepsis Surviving Campaign Guidelines, recommending crystalloids as first-line therapy, and includes the latest evidence through September 2024.

Source: Frontiers in Medicine